newsfilter
← Latest News
GlobeNewswire·

Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis

Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trialThe Company has a statistical team who are doing periodic reviews of the unblinded data to